RecruitingACTRN12605000401651
Assessment of the safety and efficacy of fondaparinux as an anticoagulant in haemofiltraion in patients with acute renal failure
Sponsor
Intensive Care Unit, RMH
Enrollment
20 participants
Start Date
Jun 4, 2004
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- The study will be conducted in the Intensive Care Unit at The Royal Melbourne Hospital and will aim to include patients who fulfill the following criteria: 1.Adult patients admitted to the ICU with an expected stay of more than 48h. 2.Patients who require continuous renal replacement therapy. 3.Patients who consent or if the patient is incompetent, the next-of-kin who consent, to inclusion in the study.
Exclusion Criteria1
- Patients who are pregnant. 2.Patients with a contra-indication to anticoagulation for pre-existing bleeding diathesis. 3.Patients or next-to-kin who do not consent to study inclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The active group will be given ondaparinux for anticoagulation for the first filter only during their course of haemofiltration.
The decision to commence or cease haemofiltraion will remain with tr
The active group will be given ondaparinux for anticoagulation for the first filter only during their course of haemofiltration. The decision to commence or cease haemofiltraion will remain with treating physician.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000401651